GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: The IUPAC descriptor for this compound was obtained from the FDA's list of Orphan Drug Designations and Approvals [1]. It maps to a chemical structure claimed in patent WO2020160054A1, for activity as a Toll-like receptor 7 (TLR7) and/or TLR8 agonist [2]. We suspect that this is CAN1012 (CanWell Pharma), a selective TLR7 agonist, but the structure of CAN1012 has not been formally disclosed.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. FDA.
Orphan Drug Designations and Approvals. Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1058824 |
|
2. Yu N. (2020)
Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof. Patent number: WO2020160054A1. Assignee: Canwell Biotech Ltd. Priority date: 28/01/2020. Publication date: 06/08/2020. |